Get the Stockscreener App
10.64
2.01%
0.21
After Hours:
10.75
0.11
+1.03%
Forte Biosciences Inc stock is traded at $10.64, with a volume of 7,306.
It is up +2.01% in the last 24 hours and down -16.61% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$10.43
Open:
$10.65
24h Volume:
7,306
Relative Volume:
0.08
Market Cap:
$70.05M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-10.23
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
+9.92%
1M Performance:
-16.61%
6M Performance:
-33.00%
1Y Performance:
-25.00%
1-Day Range:
$10.50
$10.77
1-Week Range:
$9.23
$10.77
52-Week Range:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
10.64 | 127.39M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
What analysts say about Forte Biosciences Inc. stockTriple returns potential - jammulinksnews.com
What drives Forte Biosciences Inc. stock priceFree AI-Backed Trading Signals - Autocar Professional
Is Forte Biosciences Inc. a good long term investmentLightning-fast growth - jammulinksnews.com
How the (FBRX) price action is used to our Advantage - news.stocktradersdaily.com
What makes Forte Biosciences Inc. stock price move sharplyDaily Swing Candidates - Newser
Forte Biosciences Inc. Stock Analysis and ForecastGame-changing capital returns - jammulinksnews.com
WVVI Stock Analysis and ForecastFree Bull & Bear Market Updates - Jammu Links News
Why Forte Biosciences Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
How Forte Biosciences Inc. stock performs during market volatilityTop Momentum Stock Pick - Newser
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates - insights.citeline.com
Forte Biosciences (FBRX): A Strategic Buy in Biotech's High-Reward Arena - AInvest
individual investors who own 54% along with institutions invested in Forte Biosciences, Inc. (NASDAQ:FBRX) saw increase in their holdings value last week - Yahoo Finance
(FBRX) Investment Analysis and Advice - news.stocktradersdaily.com
Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 3000E Index - MarketScreener
FBRX SEC FilingsForte Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Sell-Offs Trigger Market Turmoil For Firms - Finimize
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
Firm Advises Forte Biosciences on $75 Million Public Offering - Wilson Sonsini
Forte Biosciences (FBRX) Plans $75 Million Public Offering - GuruFocus
Forte Biosciences Announces Public Offering of Shares - TipRanks
Forte Biosciences Announces Proposed Public Offering - Bluefield Daily Telegraph
Forte’s celiac disease drug shows positive results in Phase 1b trial - Investing.com Nigeria
Forte Biosciences Announces Positive Phase 1b Trial Results - TipRanks
Forte Biosciences (FBRX) Soars 16.75% on Positive Clinical Trial Results - AInvest
Valkyrie Balance Sheet Opportunities ETF (NYSEARCA:VBB) Trading 0.4% Higher – Here’s Why - Defense World
Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
With Forte Biosciences Up 28%, Insider Buyers Count Their Returns - simplywall.st
(FBRX) Long Term Investment Analysis - news.stocktradersdaily.com
Forte Biosciences (FBRX) Receives Buy Rating as FB-102 Shows Blockbuster Potential | FBRX Stock News - GuruFocus
Forte Biosciences reports annual meeting results By Investing.com - Investing.com Nigeria
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.91%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):